Business Context and Reporting Period
Altimmune, Inc. filed a Form 8-K on March 8, 2019, reporting the entry into a Material Definitive Agreement. The Company, a Delaware corporation, entered into a Securities Purchase Agreement with two institutional investors to conduct a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
- Securities Sold: 4,361,370 units total, comprising 1,500,000 Common Units and 2,861,370 Pre-funded Units.
- Offering Price: $3.21 per Common Unit and $3.20 per Pre-funded Unit.
- Expected Proceeds: Approximately $13.0 million (net of placement agent fees, excluding warrant exercise proceeds and offering expenses).
- Warrant Terms: Each unit includes 0.70 of a warrant exercisable at $3.21 per share, expiring five years from issuance.
- Placement Agent Fees: 7% of gross proceeds paid to Roth Capital Partners, LLC, plus up to $75,000 in expense reimbursement.
Material Changes and Adjustments
The filing details an automatic adjustment to the exercise price of existing "Unit Offering Warrants" issued in October 2018. Previously adjusted from $6.00 to $4.1798, the exercise price was further adjusted upon the announcement of this Offering. The new exercise price is set to the lower of: (i) the purchase price of the new units ($3.21), (ii) the exercise price of the new warrants ($3.21), or (iii) the lowest VWAP of the common stock during the five trading days following the March 8, 2019 announcement.
Outlook, Risks, and Management Commentary
- Closing Date: The Offering is expected to close on or about March 12, 2019, subject to customary conditions.
- Investor Ownership Limits: Pre-funded Units were offered to investors who would otherwise exceed beneficial ownership thresholds of 4.99% or 9.99%.
- Legal Disclaimer: The Company explicitly states that representations and warranties in the Securities Purchase Agreement are for risk allocation between parties and should not be relied upon as factual characterizations of the Company's condition by stockholders.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after all offering expenses.
- Confirm the final adjusted exercise price of the October 2018 Unit Offering Warrants based on the five-day VWAP calculation.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and redemption rights.
- Assess the dilution impact of the 4,361,370 new units and associated warrants on existing shareholders.